Imatinib Cristers

Imatinib, the active ingredient in Imatinib Cristers, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and gastrointestinal stromal tumors, targeting malignant cell proliferation in adult patients. The drug is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor.

GNH USA supplies Imatinib Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with established quality assurance and regulatory compliance.

Imatinib acts on abnormal tyrosine kinase signaling pathways in specific hematologic malignancies and stromal tumors.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting BCR‑ABL kinase activity. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking c‑KIT and PDGFR signaling.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Edema: swelling of the extremities. - Muscle cramps: transient muscle discomfort. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: congestive heart failure or reduced ejection fraction. - Severe neutropenia: marked decrease in white blood cells increasing infection risk.

Before initiating therapy, clinicians should consider several safety factors.

- Pregnancy: contraindicated in pregnancy (Category D); avoid unless benefits outweigh risks. - Renal impairment: monitor kidney function and adjust dose if needed. - Hepatic impairment: assess liver enzymes before initiating therapy. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Cardiac monitoring: evaluate cardiac function in patients with pre‑existing heart disease. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Imatinib interacts with several medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously. - Concomitant use with QT‑prolonging agents: increased risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase imatinib levels; observe for toxicity. - Live attenuated vaccines: potential reduced efficacy; consider timing of vaccination.